Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Operations (2018 - 2025)

Arcturus Therapeutics Holdings' Cash from Operations history spans 8 years, with the latest figure at 16227000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 5613.73% year-over-year to 16227000.0; the TTM value through Dec 2025 reached 74271000.0, down 24.31%, while the annual FY2025 figure was 74271000.0, 24.31% down from the prior year.
  • Cash from Operations reached 16227000.0 in Q4 2025 per ARCT's latest filing, up from 17151000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 160259000.0 in Q4 2022 to a low of 49039000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 12758350.0, with a median of 26953000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: skyrocketed 477.11% in 2022, then crashed 5613.73% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 42497000.0 in 2021, then surged by 477.11% to 160259000.0 in 2022, then tumbled by 100.39% to 629000.0 in 2023, then surged by 54.85% to 284000.0 in 2024, then plummeted by 5613.73% to 16227000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Cash from Operations are 16227000.0 (Q4 2025), 17151000.0 (Q3 2025), and 5755000.0 (Q2 2025).